- 期刊
Effect and Safety of Mycophenolate Mofetil in Idiopathic Pulmonary Fibrosis
延伸閱讀
- Egan, J. J., Adamali, H. I., Lok, S. S., Stewart, J. P., & Woodcock, A. A. (2011). Ganciclovir Antiviral Therapy in Advanced Idiopathic Pulmonary Fibrosis: An Open Pilot Study. Pulmonary Medicine, 2011(), 30-34. https://doi.org/10.1155/2011/240805
- Chien, J. Y., Jerng, J. S., Yu, C. J., & Yang, P. C. (2004). Prognosis of Patients with Idiopathic Pulmonary Fibrosis Admitted to the Intensive Care Unit. 胸腔醫學, 19(3), 168-177. https://doi.org/10.29806/TM.200406.0001
- 蕭淑芳、吳英黛、徐紹勛、賴玉玫（2010）。The Related Factors of Exercise Capacity and Quality of Life in Patients with Idiopathic Pulmonary Arterial Hypertension。物理治療，35(1)，8-15。https://www.airitilibrary.com/Article/Detail?DocID=15632555-201003-201005200075-201005200075-8-15
- Kawasumi, H., Gono, T., & Yamanaka, Y. K. A. H. (2015). Recent Treatment of Interstitial Lung Disease with Idiopathic Inflammatory Myopathies. Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine, (2015-S1), 9-17. https://doi.org/10.4137/CCRPM.S23313
- Hayton, C., & Chaudhuri, N. (2017). Current Treatments in the Management of Idiopathic Pulmonary Fibrosis: Pirfenidone and Nintedanib. Clinical Medicine Insights: Therapeutics, 2017(), 1-4-013. https://doi.org/10.1177/1179559X17719126